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Abstract

Tramadol is a centrally acting analgesic, atypical opioid, and although it is generally
considered as a medicinal drug with a low potential for dependence, there is growing evidence of
tramadol abuse in some countries. The ultraviolet detection is not suitable for analysis of tramadol in
plasma, due to the lack of sensitivity and selectivity. However, it was shown that tramadol has a weak
fluorescence, and the latest techniques for determination of tramadol in plasma include liquid
chromatographic methods with fluorescence detection (FL). The objective of the paper was to
develop a HPLC-FL method applicable for quantification of tramadol in human plasma.The
separation was achieved by reverse phase HPLC method, using as stationary phase C18 – Kromasil®
column and a mobile phase consisted of acetonitrile:0.1% formic acid (20:80). The fluorescence
detection has been applied with λex/em= 280/310 nm. A solid phase extraction procedure using C18
cartridge was carried out.
The linearity of the method has been demonstrated in the range of both therapeutic and toxic
plasma tramadol levels (concentrations of 0.100 – 1µg/mL). The selectivity, precision, and accuracy
of the method have been demonstrated. The limit of detection (LOD= 0.010 µg/mL) and the limit of
quantification (LOQ = 0.100 µg/mL) have been established.The proposed method can be used to
assess tramadol levels in human plasma in pharmacokinetic studies, as well as in overdose cases. The
utility of the method for the quantification of therapeutic levels of tramadol has been shown on the
plasma samples from the patients with tramadol treatment as analgesic (doses ranging from 100 mg
to 400 mg/day).The developed method is rapid, using simple experimental conditions and an accurate
and short extraction procedure.
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Introduction

fluorescence spectrum of both parent drug and two

The Tramadol is a central analgesic, atypical major metabolites, O-desmethyltramadol and Nopioid, widely used in therapeutics, but frequently desmethyltramadol are not virtually identical.
reported in cases of drug-related deaths (1). Consequently,

various

publications

reported

Therapeutic plasma concentrations, usually found different sensitivities of spectrofluorimetric or
after a 50-100 mg dose, can vary up to 0.3 µg/mL, HPLC with fluorescence detection methods for the
while the toxic levels are generally around 1 quantification of tramadol.
µg/mL.

Bahrami G. reported a HPLC method with

In general, HPLC methods, reported in fluorescence
literature, for quantification of tramadol, use the derivatization

detection,
with

involving

pre-column

9-fluorenylmethyl

chloro

UV (at 280 nm) or fluorescence detection, and the formate, leading to increased fluorescence
separation is typically obtained on C-18 intensity of tramadoland an increase in detection
(egPhenomonex® Gemini C-18, Hypersil® C18) and quantitation limits respectively (8).
columns.

The

mobile

phases

used

contain
Gu Y et al. reported a HPLC method with

phosphate buffer-methanol-acetonitrile (11) or

35% acetonitrile and aqueous solution with 20mM fluorescence detection (wavelengths of excitation
sodium phosphate buffer, 30mMsodium dodecyl and emission of 275 and 300 nm) for
sulfate and 15mMtetraethylammonium bromide, quantification of tramadol and its active metabolite
O-desmethyltramadolul in human plasma (2). A
pH 3.9 (2).
Although tramadol has a core structure of
benzene nucleus, UV detection is not suitable for
its analysis in plasma, due to the lack of sensitivity

liquid-liquid extraction procedure was carried out
using

dichloromethane-diethyl

(5:3:2), followed by extraction with sulfuric acid;
tramadol,

and selectivity (3).

ether-butanol

O-desmethyltramadol

and

internal

standard, sotalol, were separated on a Hypersil®
Latest

techniques

for

determination

of

C18 column.

tramadol include electrochemical methods (4),
mass spectrometry (5), capillary electrophoresis

Ebrahimzadeh

H.

and

coworkers

have

(6) and HPLC with fluorescence detection (3, 7), developed a HPLC method with fluorescence
the latter giving better selectivity and sensitivity.

detection (wavelengths of excitation and emission

It has been shown that tramadol has a weak of 200 and 301nm respectively) to quantify
fluorescence, with a maximum of emission at 300 tramadol and O-desmethyltramadol in human
nm, after excitation at 200 nm. In addition, the plasma and urine (9). Separation was achieved on a
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RP-18e Chromolith® Performance column using as



Water for chromatogtaphic use (obtained

mobile phase methanol: water with phosphoric

with Barnstead®EasypureRoDi system)

acid, at pH 2.5 (19:81).

Materials

A HPLC method with fluorescence detection



(excitation and emission wavelength of 200 nm

Solid phase extraction cartridges, DSC 18
(Supelco)

and 295 nm) for determination of tramadol and Odesmethyltramadol in plasma was proposed by



Chromatographic column: Kromasil®, 150

Curticapean A. et al. working on a RP18column

mm x 4.6 mm, 5 μm; C18stationary phase

with C18 pre-column, with elution gradient over

Apparatus:

26 minutes, with the mobile phase consisting of
phosphoric

acid,

triethylamine,

methanol,



Liquid-chromatograph

acetonitrile (10). Liquid-liquid extraction with

(Thermo

ethyl acetate and sotalol as internal standard were

following modules:

used.

-

Corp.),

Plus

with

the

DAD (diode array detector), with a
specialized program for the determination

Based on the literature data review

of the spectral purity for eluted compounds

regarding the methods of quantification of
tramadol, mainly in biological samples, we have

Electron

Surveyor

-

Fluorescence detector

-

Quaternary pump with vacuum degasser

-

Autosampler with thermostat (Peltier)

-

Column

proposed the development of a HPLC method with
sensitive fluorescence detection, rapid and suitable
for routine clinical laboratories and forensic
toxicology everyday use, in order to determine
acute intoxication with tramadol.

compartment

with

thermostat

(Peltier)
Materials and method
Chemicals and apparatus:
Reference standards and active substances:


Tramadol hydrochloride (Sigma Aldrich)



Elma)


Analytical balance (Ohaus)



Evaporator under nitrogen stream (Techne

Reagents:


Methanol Chromosolv for HPLC (Merck)



Acetonitrile Chromosolv for HPLC (Merck)



Formic acid (Merck)

Ultrasonic bath (Elmasonic S60 /Hmodel,

Dry-Block DB-3Dmodel, Bibby
ScientíficInc.)


Solid phase extraction system (Visiprep
Manifold model, Supelco)
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 Refrigerated centrifuge Sigma 2-15 K (Sigma)

Biological material
 Human plasma obtained from peripheral venous

blood provided by a Hematology Institute

Control samples
The „simulated” (spiked) human plasma
controls

were

prepared

at

the

following

concentrations: 0.1 µg/mL, 0.5 µg/mL and 1
µg/mL.

Methodology
Tramadol extraction procedure from plasma
Chromatographic conditions
A solid phase extraction procedure was
 Mobile phase: 0.1% formic acid: acetonitrile

(20:80)

applied: at 1 mL plasma add 200 µLNaOH 0.1
mol/L; the mixture is subject to vortex stirring for

 Flow rate: 1 mL/min

2 minutes, then it is slowly passed in the solid

 Column temperature: 22°C

phase extraction system, over DSC 18cartridge,

 Sample temperature: 20°C

previously

wetted

with

methanol

(2

mL).

Subsequently, the analyze is eluted from the
 Fluorescence detector: λ ex= 280 nm and λem= cartridge with methanol (2 mL); the extract is

310 nm
 Elution: isocratic
 Injection volume: 20 µL

centrifuged at 3000 rpm for 10 minutes, then it is
evaporated to dryness under nitrogen stream. The
residue was sampled in with 500 μL mobile phase,
sonicated for 1-2 minute and then the samples

 Analysis time : 6.5 minutes

Preparation of solutions
Tramadol stock solution: 10 mg of tramadol
hydrochloride were quantitatively transferred into
a 10 mL volumetric flask, dissolved in methanol
and diluted to volume with the same solvent.

obtained were injected into the HPLC system.
Analytical method validation
The method validation was carried out in
accordance with FDA Guidance for IndustryBioanalytical

Method

Validation,

DRAFT

guidance, 2013 (11).

Tramadol working solution (10 µg/mL) was
prepared by dilution with mobile phase, from the
stock solution.

The experimental data was analyzed with
Chromquest 4.2 data processing software.
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Results

phase. We checked the possibility of using a

Development and validation of the method

simple mobile phase, containing methanol and
0.2% formic acid solution in a 65:35 ratio; in these

In the elaboration of HPLC tramadol dosing
method we start from the literature data, indicating
the

use

of

C18

chromatographic

columns.

Recommended mobile phases contain mostly
acetonitrile or methanol, mixed with various buffer

experimental conditions we cannot achieve an
appropriate symmetry peak, and the retention time
is very short (about 1,2 min.) and susceptible to
interference with unretained compounds and
plasma separated compounds.

solutions (phosphate, triethylamine, acetate, formic
acid) with pH between 2.5 and 7.3.

100
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FL Plus
tramafl 0.5 microre
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20698
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5.077

4.160 3958
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10189
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3.597
3.5

3.713 4948

2.933 22393

3.403 6434
3.497 15166

3.220 6520
3.310 8714

3.113 6051

2.737 4401

10793

2.290 12084
2.373 13880
17877
2.437

2.190

2.063 5305

2.0

2.623 7047

40267

10449
1.910

16479

13784

1.397 50444

1.547

1.273

1.707

1.017 8833
1.093 4893

0

0.390 52566

0.157
0.210 2362
952

subject of much interference, and based on the

0.837 10049

excitation wavelength of 200 nm is likely to be

0.647 3235

FU

were typically 200/295, 301 or 275/300. Since the

80

70

FU

The wavelengths of excitation and emission

0

6.5

Minutes

280 nm (12), we established the following

Figure 1.Chromatogram of tramadol

experimental conditions for the fluorescence

hydrochloride standard solution of 0.1 µg/ mL

detection

used for HPLC

determination of

tramadol: λex = 280 nm, λem = 310 nm.

Given these results, we resorted to a mobile
phase of acetonitrile and 0.1% formic acid, the

We selected the chromatographic column proportions being determined by successive trials:
after testing three types of chromatography column 30:70 (TR = 2.25 min.), 25:75 (TR = 2 , 5 min.),
with octadecylsilyl stationary phase 5 mm (C18): 20:80 (TR = 4.65 min.). Based on these
Symmetry® 3.9 mm x 150 mm, 4.6 mm x 150 mm, determinations, we selected a mobile phase of
Kromasil®4.6 mm x 150 mm and Hypersil Gold® acetonitrile and 0.1% formic acid 20:80 (Figure1).
4.6 mm x 100 mm. Kromasil column provided
suitable results in terms of analysis time. The 5

We established the calibration curve using
concentrations

of

tramadol

hydrochloride

retention time of tramadol is approximately 4.7 solution in the concentration range of 0.1 µg / mL min, in the working conditions, using a mixture of 1 µg / mL (0.1 µg / mL, 0.25 µg / mL, 0.5 µg / mL;
acetonitrile - 0.1% formic acid (20: 80), as mobile 0.75 µg / mL and 1 µg / mL). This concentrations
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domain coversboth therapeutic (from 0.1 to 0.3 µg determination carried out on different days; the
/ mL) and toxic/lethal (1 µg / mL and 2 µg / mL) experimental data are summarized in Table. 1.
levelsof tramadol (13). Three replicate injections
The detection and quantification limits were
from

each

solution

were

performed.

The

experimental data well fitthe model of linear
equations y = A + Bx, as we obtained aregression
equation y = 1.70311e-007x - 0.00338394 with a

established based on the signal – noise ratio, by
recording chromatograms and measuring the
signals

corresponding to

reference solutions

tramadol hydrochloride at concentrations of 0.01

correlation coefficient of 0.997414.

μg/mL - 1μg/mL.The value obtained for the limit
of detection (DL) was of 10 ng / mL, while the

Discussions

limit of quantification (QL)was set at 100 ng/mL, a
The

precision

of

the

method

was
level at which both precision and accuracy have

determined as repeatability in the linearity study of
been determined.
the method. Based on the results (analysis report
Table 1HPLC method for determination of

The specificity/selectivity of the method
were determined by recording and comparing of

tramadol hydrochloride - intermediate precision
RSD (%)

the chromatograms of solutions obtained by

Tested

Average

concentration

concentration

addition

(μg/mL)

found (µg/mL)

plasma).

0.1

0.092

5.2

0.5

0.45

3.78

1.0

0.96

4.56

Average

-

4.51

processing plasma (blank), and plasma with the
of

tramadolhydrochloride

(spiked

The extraction from plasma samples was
performed by solid phase technique (SPE), at
alkaline pH, using DSC C18 extraction cartridges
(Supelco). The chromatograms shown in the
Figure 2 demonstrate the selectivity of the method;
no other compound from plasma elutesat the

provided by the software Chromquest 4.1, data not retention time of analyze. Thus, the extraction
shown), the method proved to be precise (RSD ≤ procedure is appropriate regarding tramadol peak
2%). In addition, the intermediate precision was symmetry and separation from other plasma
examined

at

threeconcentration

levels,

by generated peaks.
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The method accuracy, as average recovery, is

Bucharest. Samples were obtained under the

within acceptance limits according to FDA informed consent of the patients.
guidelines. In our experiments we followed the
possibility of a simple procedure of processing

100

samples, involving only deproteinization with
however,
shorter

100

FL Plus
tmdprlasma05

isolation

90

90

80

80

70

70

60

60

50

50

40

40

30

30

regardinganalysis
FU

method,although

this

FL Plus
plasma trmd 0.5 micro re

time,cannot be applied, as many interferenceswith
tramadol

peak

are

obtained

(possible

1.917

the

FU

acetonitrile;

FL Plus
tmdpplasmac

Retention Time

Tramadol
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dosing
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in
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patients treated with tramadol

Figure 2. The selectivity of the HPLC method for
determination of tramadol(blank plasma and plasma

Weverified the applicability of the HPLC
method with fluorescence detection for the

spiked with tramadol 0.5 µg/mL - 2 samples, SPE

determination of tramadol in patients receiving

extraction procedure)

tramadol, hospitalized at an Oncology Clinic from

Table 2. The accuracy (as percentage of recovery after extraction) of HPLC method for the
determination of tramadol in plasma
Concentration (µg/mL)

0.1

0.5

1.0

Average recoveypercentage(%)

87.56

86.37

91.2

Standard error

0.92

6.20

1.84

Standard deviation

1.83

12.41

3.69

CV

0,97%

6,98%

1,96%

Averagerecovery: 88.37%

6.5

Minutes
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Plasma samples were analyzed in 6 patients phase extraction, is simple, accurate and requires a
(5 women and one man) with cancer, treated with shorter analysis time than liquid-liquid processes.
tramadol as an analgesic in doses ranging from 100
200

mg to 400 mg/day, as tablets, capsules or injection.
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tmdproba1
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3618388
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1.917
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100

2503274
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343.588940

Experimental data indicate that tramadol
has been identified in plasma in 5 of the 6
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S/N (6 sigma)
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patients;the plasma levels determined were in

37.361427

40

0

6.5

Minutes

µg/mL in 2 patients (Figure3); these patients

Figure 3.Chromatograms obtained from

received tramadol dose of 200 mg/day orally or

plasma tramadol dosage in patients receiving

300 mg / day injection (14).

tramadol (pacients 1 and 5)

In samples obtained from three patients,

Conclusions

the quantification of tramadol could not be

 Considering the native fluorescence of

achieved as interferences were observed. There

tramadol, and based on the literature data,

were other compounds extracted from the sample

we developed and validated a new HPLC

plasma that co-eluted with tramadol (data not

method with fluorescence detection for the
determination

shown). The results suggested a similar therapeutic
scheme in the treatment of these three patients.
The experimental results show that the

of

tramadol

in

human

plasma.
 The method uses simple experimental
conditions: Kromasil column (C18 bound
phase), mobile phase acetonitrile: 0.1%

developed

HPLC

method

with

fluorescence

formic acid, the fluorescence detection,

detection can be applied for determination of

λex/em = 280/310 nm for 6.5 minutes

tramadol at therapeutic levels in plasma. In

analysis time, applying SPE procedure

addition, the proposed extraction method - solid

from plasma on C18 cartridge.
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 The developed method is selective, is linear

3. Chan EC, Ho PC. Enantiomeric separation

on concentration range of 100 ng - 1 μg/

of

mL, corresponding to both therapeutic and

metabolites

the toxic/lethal tramadol levels, and has the

capillary

detection/quantification

Chromatogr B Biomed Sci Appl. 1998;

limitsof

0.010

μg/mL and 0. 100μg/mL respectively. In
addition,

the

useof

the

fluorescence

tramadol

hydrochloride
by

and

its

cyclodextrin-mediated

zone

electrophoresis.

J

707(1-2):287-94.
4. Curticapean A, MunteanD, CurticapeanM,

detector contributes, in itself, to increasing

DogaruM,

VariC.

Optimized

HPLC

the selectivity of the method.

method for tramadol and O-desmethyl

 The applicability of HPLC-FL method was

tramadol determination in human plasma.

verified for determination of tramadol in

J. Biochem. Biophys. Methods 2008;70:

plasma in patients treated with tramadol.

1304–1312.

for

5. Ebrahim ZAJ, Bălălău D, Baconi DL, Guţu

quantification of therapeutic levels of

CM, Ilie M.HPTLC method for the assay of

tramadol has been demonstrated.

tramadol and pentazocine from mixtures.

Thus,the

utility

of

the

method

Farmacia 2011; 59(3): 381–387.
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